Fig. 2. (A) Photographs of the clinical features of NC/Nga mice non-treated (NT), 2,4-dinitrochlorobenzene (DNCB)+vehicle (VH), DNCB+1% eupatilin cream, DNCB+0.03% tacrolimus ointment, on day 29 following the first challenge. (B) Clinical skin severity scores. (C) Ear thickness. Photos and graphs revealed that 1% eupatilin cream significantly reduced the clinical signs such as erythema, edema, excoriation, and dryness on day 29, compared to the vehicle only (p<0.05). Data are presented as mean±standard error of the mean (n=5). ^*p<0.05, compared to the vehicle group.